IMARC Group, a leading market research company, has recently released a report titled "Radiopharmaceuticals Market Report by Product Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), End Use (Hospitals and Clinics, Research Institutes, Diagnostic Centers), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global radiopharmaceuticals market Trends, size, share, growth and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Radiopharmaceuticals Market Overview:

The global radiopharmaceuticals market was valued at USD 5.8 Billion in 2024 and is forecast to grow to USD 8.9 Billion by 2033, exhibiting a CAGR of 4.9%. This growth is driven by technological advancements in imaging, rising incidences of chronic diseases such as cancer and cardiovascular disorders, and supportive government regulations worldwide. The market report provides insights by product type, application, end use, and region over the forecast period of 2025-2033.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Radiopharmaceuticals Market Key Takeaways

• The global radiopharmaceuticals market size was USD 5.8 Billion in 2024.
• The market is expected to grow at a CAGR of 4.9% during 2025-2033.
• Forecast value of the market is USD 8.9 Billion by 2033.
• Major drivers include the increasing incidence of chronic diseases such as cancer and cardiovascular disorders and advancements in PET and SPECT imaging technologies.
• Theranostics with dual diagnostic and therapeutic functions is a key trend shaping the market.
• North America leads the market due to strong healthcare infrastructure and high expenditure.
• Emerging economies in Asia-Pacific like China and India are expected to witness rapid growth.

Request Your Free “Radiopharmaceuticals Market” Insights Sample PDF: https://www.imarcgroup.com/radiopharmaceuticals-market/requestsample

Market Growth Factors

During the forecast period, chronic diseases rise in prevalence within. Advanced imaging, diagnosis, and therapeutic techniques like radiopharmaceuticals are required for cancer and cardiovascular diseases. This is expected to grow the market. A Centers for Disease Control and Prevention report states over 1.6 million new cancer cases occurred in the United States during 2020, and this is expected to drive market growth.

Technical advancing of imaging technologies, particularly positron emission tomography (PET) and single photon emission computed tomography (SPECT), allows, for example, doctors to diagnose diseases such as cancer, neurological disorders, and cardiac diseases early. In 2023 the global PET market was projected at USD 1.1961 Million and is expected to reach USD 1.93 Billion by 2032 at a CAGR of 5.33% during the period.

That the US and Europe regulate in a conducive manner has been one factor that propels market growth. Regulatory agencies like the FDA and EMA have streamlined radiopharmaceutical product approval processes now. Additionally, incentives like Orphan Drug Designation status encourage the pharmaceutical industry to develop precision-targeted radiopharmaceuticals therapies.

Market Segmentation

Breakup By Product Type:

• Diagnostic Nuclear Medicine: This segment holds the majority market share. It involves administration of radiopharmaceuticals primarily used for imaging through PET and SPECT modalities. Increasing prevalence of cancer, cardiac, and neurological diseases drive demand.
• Therapeutic Nuclear Medicine: Focuses on therapeutic applications of radiopharmaceuticals to treat various diseases. Investments in R&D aim to improve treatment efficacy and safety.

Breakup By Application:

• Oncology: The dominant application segment benefiting from targeted cancer therapies and precision medicine. Radiopharmaceuticals enable diagnosis, staging, and post-treatment evaluation through advanced imaging.
• Cardiology: Used for diagnosing and managing cardiac disorders using nuclear imaging techniques.
• Neurology: Supports diagnosis and monitoring of neurological conditions.
• Endocrinology: Applied in imaging and treatment focused on endocrine system disorders.
• Others: Covers additional medical applications utilizing radiopharmaceuticals.

Breakup By End Use:

• Hospitals and Clinics: Medical centers providing treatment and diagnostic services involving radiopharmaceuticals.
• Research Institutes: Entities engaged in R&D activities related to radiopharmaceuticals.
• Diagnostic Centers: The leading end-use segment focusing on nuclear imaging procedures for accurate diagnosis. Includes adoption of hybrid imaging technologies like PET, SPECT, and new innovations such as XENOVIEW hyperpolarized contrast agent approved by the FDA.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the global radiopharmaceuticals market due to its strong healthcare infrastructure, high healthcare expenditure, technological advancements, and presence of established players. According to the Centers for Medicare & Medicaid Services, US healthcare spending reached $4.5 trillion in 2022, growing 4.1% from the previous year. The insured population rose to 92% with increased private insurance and Medicaid enrollments. Government support and high disease prevalence foster market growth, innovation, and product introduction acceleration.

Recent Developments & News

In March 2023, the International Atomic Energy Agency (IAEA) launched the Rays of Hope partnership collaborating with 11 Japanese universities to enhance cancer care in Asia and the Pacific. In February 2024, Bristol Myers Squibb completed the acquisition of RayzeBio, expanding its portfolio with an actinium-based radiopharmaceutical platform aimed at treating solid tumors, marking a significant step in the growing radiopharmaceutical therapeutics market.

Key Players

• Advanced Accelerator Applications (Novartis AG)
• Bayer AG
• Bracco S.p.A.
• Cardinal Health Inc.
• Curium Pharma
• General Electric Company
• IBA RadioPharma Solutions
• Jubilant Pharma Limited
• Lantheus Medical Imaging Inc
• Nordion Inc. (Sotera Health)
• NTP Radioisotopes SOC Ltd
• PharmaLogic Holdings Corp.
• Siemens AG

Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=3906&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302